Can you take Olaparib with Rilonacept?

Rilonacept has a moderate potential interaction with High Cholesterol.

Patients treated with rilonacept experienced increases in their mean total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides. The mean increases from baseline for total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides were 19 mg/dL, 2 mg/dL, 10 mg/dL, and 57 mg/dL respectively after 6 weeks of open-label therapy. Physicians should monitor the lipid profiles of their patients especially those with hyperlipidemias, and consider lipid-lowering therapies as needed based upon cardiovascular risk factors and current guidelines.

Rilonacept has a moderate potential interaction with Infection.

Interleukin-1 (IL-1) blockade may interfere with the immune response to infections. Treatment with other medication as rilonacept, that work through inhibition of IL-1 has been associated with an increased risk of serious infections, and serious infections have been reported in patients taking rilonacept compared with placebo. Rilonacept should be discontinued if a patient develops a serious infection. Treatment with rilonacept should not be initiated in patients with an active or chronic infection. Additionally, latent tuberculosis can be reactivated and should be treated before initiating therapy with rilonacept.

Olaparib has a moderate potential interaction with Liver Disease.

Olaparib primarily undergoes hepatic metabolism via CYP450 3A4 and CYP450 3A5; the majority of metabolism is through oxidation with some metabolites undergoing subsequent glucuronide or sulfate conjugation. No dose adjustment is needed in patients with mild hepatic impairment. It is recommended to use caution when using olaparib in patients with moderate or severe hepatic impairment as there are no data available. Close monitoring is recommended.

Rilonacept has a moderate potential interaction with Liver Disease.

No formal studies have been conducted to examine the pharmacokinetics of rilonacept administered subcutaneously in patients with hepatic impairment. Caution is advised if used on these patients.

Olaparib has a moderate potential interaction with Myelodysplastic Diseases.

Olaparib might cause Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML), sometimes with fatal outcomes. Care should be exercised when using olaparib in patients with a history of previous cancer or bone marrow dysplasia. Do not start olaparib until patients have recovered from hematological toxicity caused by previous chemotherapy (<= Grade 1). It is recommended to monitor patients for hematological toxicities at baseline and monthly thereafter for clinically significant changes during treatment. Interrupt olaparib for prolonged hematological toxicities and monitor blood counts weekly until recovery and discontinue treatment if MDS/AML is confirmed.

Olaparib has a moderate potential interaction with Pulmonary Impairment.

Pneumonitis, including fatal cases, occurred in <1% of patients treated with olaparib. It is recommended to interrupt treatment if patients present new or worsening respiratory symptoms such as dyspnea, cough and fever, or a radiological abnormality. Assess for the source of symptoms and if pneumonitis is confirmed, olaparib should be discontinued and the patient treated appropriately.

Olaparib has a moderate potential interaction with Renal Dysfunction.

In a olaparib renal impairment trial, the mean AUC increased by 24%, and the Cmax increased by 15%, in patients with mild renal impairment. In patients with moderate renal impairment, the AUC increased by 44% and the Cmax by 26%. No dose adjustment is needed in patients with mild renal impairment. The dose of olaparib in patients with moderate renal impairment should be adjusted according to the prescribing information. It is recommended to monitor for toxicity all patient with renal impairment. The pharmacokinetics of olaparib have not been evaluated in patients with severe renal impairment or end-stage renal disease.

Rilonacept has a moderate potential interaction with Renal Dysfunction.

No formal studies have been conducted to examine the pharmacokinetics of rilonacept administered subcutaneously in patients with renal impairment. Caution is advised if used on these patients.

Rilonacept has a moderate potential interaction with Tuberculosis, Latent.

Interleukin-1 (IL-1) blockade may interfere with the immune response to infections. Treatment with other medication as rilonacept, that work through inhibition of IL-1 has been associated with an increased risk of serious infections, and serious infections have been reported in patients taking rilonacept compared with placebo. Rilonacept should be discontinued if a patient develops a serious infection. Treatment with rilonacept should not be initiated in patients with an active or chronic infection. Additionally, latent tuberculosis can be reactivated and should be treated before initiating therapy with rilonacept.

Rilonacept has a major potential interaction with Vaccination.

Live vaccines should not be given concurrently with rilonacept. Rilonacept may interfere with normal immune response to new antigens; therefore, vaccinations may not be effective in patients receiving rilonacept. No data are available on the effectiveness of vaccination with inactivated (killed) antigens in patients receiving rilonacept. Because IL-1 blockade may interfere with immune response to infections, it is recommended that prior to initiation of therapy with rilonacept adult and pediatric patients receive all recommended vaccinations, as appropriate, including pneumococcal vaccine and inactivated influenza vaccine.